title: Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?
authors.affiliation: Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Black
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Bauer
authors.forename: Ann V
authors.initials: AV
authors.lastname: Schwartz
authors.forename: Steven R
authors.initials: SR
authors.lastname: Cummings
authors.forename: Clifford J
authors.initials: CJ
authors.lastname: Rosen
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology; D004334:Drug Administration Schedule; D050723:Fractures, Bone / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012306:Risk; D016103:Spinal Fractures / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates